



FSD Pharma Investor Factsheet

CSE: HUGE | OTCQB: FSDDF | FRA: 0K9

About the Company

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The mission of the company's wholly-owned subsidiary FV Pharma Inc. is to transform the former Kraft plant in Cobourg, Ontario, into the largest hydroponic indoor cannabis production and processing facility in the world. Facility operations include cultivation, recreational channels, hemp processing, manufacturing, oil extraction, and research & development. Currently 25,000 square feet is available for production at its Ontario facility with an additional 220,000 square feet currently in development. The FSD facility is based on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

Cannabis Production at the Cobourg Facility

- 1-hour drive from Toronto, Ontario
- Indoor hydroponic production ensures product consistency 365 days per year.
- Operations under one roof to create economies of scale and cost efficiencies, allowing control of product quality and costs of production and cultivation.
- On-site: electrical sub-station, natural gas line, railway line into the facility with a capacity for 3 rail cars, helipad onsite, 28 truck loading docks and 7 oversized drive-in doors.

Strategic Investments and Partnerships

Strategic Investment in Pharmastrip Corp

- FSD Pharma signed a definitive collaboration and profit-sharing agreement with Pharmastrip including a strategic investment of \$1.5mm in Pharmastrip Corp.
- FSD will install Pharmastrip's proprietary equipment at its facility in Cobourg, Ontario. FSD will use the equipment to manufacture organic medical cannabis infused in oral thin film strips.
- Pharmastrip will grant FSD an exclusive, perpetual license to manufacture and sell the oral thin film strips in Canada.

Strategic Investment in Cannara Biotech Inc.

- FSD Pharma will occupy over 105,000 square feet of Cannara's facility located within a one-hour drive from Montreal.
- Cannara is under way in the application process under the ACMPR and plans to be the largest indoor cultivation facility in Quebec.

Strategic Investment in High Tide Inc.

- High Tide operates a chain of cannabis accessory stores in Canada.
- Currently developing retail stores for cannabis sales.
- Applied for 31 retail cannabis permits in Alberta, and applications submitted for British Columbia.
- Owns 4 of Canada's most prominent retail brands: RGR Canada Inc., Smokers Corner (largest chain of cannabis accessory stores in Canada), Canna Cabana, and subject to shareholder approval, will own Famous Brandz).
- Owns exclusive rights to produce Trailer Park Boys and Snoop Lion cannabis merchandise.

Strategic Investment in Huge Shops

- FSD Pharma completed a strategic investment of \$1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer.
- Huge Shops has a strategic alliance with Chairman's Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada.
- Huge Shops stores will be branded and operated independently.

Strategic Alliance with SciCann Therapeutics

- Canadian-Israeli specialty pharmaceutical company dedicated to the development and commercialization of novel and disruptive pharmaceutical products.
- FSD Pharma has invested \$3M for an equity stake in SciCann.
- FSD Pharma has an exclusive license in Canada for the production and distribution of a line of proprietary cannabinoid-based, patent pending and indication-specific products developed by SciCann.

Collaboration/Profit-Sharing Agreement with Canntab Therapeutics Ltd.

- FSD Pharma will provide 10,000 square feet of facility space at its Coburg facility with a profit sharing and royalty agreement.
- Canntab has developed an in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained for therapeutic use in pill form.

World Class Extractions Collaboration

- FSD Pharma will provide WCE with up to 5,000 sq.ft. of space at the FSD Facility and will assist it in obtaining an extraction license.
- WCE has invented a proprietary patent pending cannabis and hemp extraction process that can extract huge amounts of oil daily on a continuous flow basis from wet or dry input material.
- FSD Pharma will provide the raw cannabis needed to produce cannabis extracts. In return, WCE will provide FSD Pharma with certain royalty rights over the profits derived from the sale of cannabis extracts.

Recent News

- FSD Pharma Announces Signing of LOI with Solarvest (TSX-V: SVS) to Develop and Test Pharma-Grade Cannabinoids out of Algae. FSD Pharma and Solarvest plan to develop a research project for the purpose of developing a proof of concept that algae can express cannabinoids.
- FSD enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop for CBD extraction.